

Robert W Cook

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7739296/publications.pdf>

Version: 2024-02-01

33
papers

1,226
citations

471371

17
h-index

434063

31
g-index

35
all docs

35
docs citations

35
times ranked

878
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 175-183.	3.2	227
2	Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 780-785.e3.	0.6	148
3	Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. <i>BMC Cancer</i> , 2018, 18, 130.	1.1	117
4	Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 149-157.e4.	0.6	72
5	Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. <i>Journal of Hematology and Oncology</i> , 2017, 10, 152.	6.9	63
6	Guidance of sentinel lymph node biopsy decisions in patients with T1â€“T2 melanoma using gene expression profiling. <i>Future Oncology</i> , 2019, 15, 1207-1217.	1.1	59
7	Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. <i>Current Medical Research and Opinion</i> , 2016, 32, 1599-1604.	0.9	55
8	Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 361-369.	0.6	51
9	Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 745-753.	0.6	50
10	Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profileâ€“based classification. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 818-825.e3.	0.6	44
11	Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study. <i>Journal of Oncology</i> , 2016, 2016, 1-9.	0.6	42
12	Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. <i>Clinical Ophthalmology</i> , 2014, 8, 2449.	0.9	39
13	Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients. <i>Diagnostic Pathology</i> , 2018, 13, 13.	0.9	37
14	Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. <i>Journal of Surgical Oncology</i> , 2019, 119, 175-186.	0.8	32
15	Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients. <i>SKIN the Journal of Cutaneous Medicine</i> , 2018, 2, 111-121.	0.1	29
16	Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics. <i>Diagnostic Pathology</i> , 2017, 12, 59.	0.9	24
17	Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. <i>JCO Precision Oncology</i> , 2021, 5, 589-601.	1.5	20
18	Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management. <i>Current Medical Research and Opinion</i> , 2020, 36, 1301-1307.	0.9	18

#	ARTICLE	IF	CITATIONS
19	Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction. <i>JCO Precision Oncology</i> , 2021, 5, 1466-1479.	1.5	17
20	Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging. <i>Journal of Drugs in Dermatology</i> , 2018, 17, 196-199.	0.4	16
21	Adjuvant therapy for high-risk cutaneous squamous cell carcinoma: 10-year review. <i>Head and Neck</i> , 2021, 43, 2822-2843.	0.9	13
22	Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 1295-1300.	0.9	10
23	Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients. <i>Journal of Clinical Oncology</i> , 2016, 34, 9581-9581.	0.8	9
24	Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study. <i>Current Medical Research and Opinion</i> , 2022, 38, 1267-1274.	0.9	8
25	Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations. <i>Future Oncology</i> , 2021, 17, 517-527.	1.1	6
26	The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma. <i>Future Oncology</i> , 2021, 17, 5023-5031.	1.1	6
27	Risk Stratification of Patients with Stage I Cutaneous Melanoma Using 31-Gene Expression Profiling. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021, 14, E61-E63.	0.1	5
28	Using a 31-Gene Expression Profile Test to Stratify Patients with Stage I-II Cutaneous Melanoma According to Recurrence Risk: Update to a Prospective, Multicenter Study. <i>Cancers</i> , 2022, 14, 1060.	1.7	3
29	Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients. <i>Diagnostic Pathology</i> , 2022, 17, 32.	0.9	3
30	Response to: "Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients?" <i>Journal of the American Academy of Dermatology</i> , 2019, 80, e163-e164.	0.6	1
31	Reply to Problematic methodology in a systematic review and meta-analysis of DecisionDx-Melanoma. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e359-e360.	0.6	1
32	Impact of a Prognostic 40-Gene Expression Profiling Test on Clinical Management Decisions for High-Risk Cutaneous Squamous Cell Carcinoma. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s64.	0.1	1
33	Comments on Post-Publication Discussion of "Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma". <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0